Replies to post #18251 on Intellect Neurosciences Inc. (fka ILNS)

[itwillgetbetter]

To hear some its a scam thats why Pfizer,GSK and Shire signed licensee agreements with intellect and have and are spending hundreds of millions of dollars on the science.

What a crock of horse crap.Don't have a idea about market cap but its not if imo its when they file orphan drug status for SHP622 F/A its going to go down per the math some are using which makes me laugh.

You see your 2 bucks when it occurs.I already know when the final data will be announced or was told by the ones in control collecting the data.Years end give or take 60 days.

Now Shire already has a idea of what they going to do.You think they don't know whats occured already.Hell they paid for this trial.

You never know what info one can get talking to others and using back doors imho not saying I used the back door but I would swim the English channel to get a heads up before anyone else!

[TrueTrades]

A: $54 per share.
§ILNS

[john1045]

If any or all of the current trials moving to completion in next few months and data is strong with no side effects, ILNS will be bought at a fair and reasonable figure IMO. My instinct tells me Maza will negotiate the best deal and like I said friedreich's ataxia data is strong, Shire will buy them out or Pfizer with Ponezumab. This is chump change for these companies. What is $30M,$40M,or $150M for ILNS portfolio that will generate hundreds of million if not billions in revenues.

From National Institute of Neurological Disorders and Stroke

There is currently no effective cure or treatment for Friedreich's ataxia.